Table 1.
Common lenvatinib-emergent adverse events
| Lenvatinib-emergent adverse events | Grade 1–2n (%) | Grade 3n (%) | Median time to first onset, weeks (IQR) | Median time to last resolution, weeks (IQR) |
|---|---|---|---|---|
| Diarrheaa | 152 (58) | 23 (9) | 12.1 (4.1, 23.7) | 18.1 (2.3, 40.9) |
| Fatigue/asthenia/malaise | 147 (56) | 27 (10) | 3.0 (1.1, 7.0) | 16.3 (4.6, 36.6) |
| Proteinuria | 58 (22) | 26 (10) | 6.1 (4.0, 15.6) | 8.8 (4.0, 24.6) |
| Rashb | 58 (22) | 1 (0) | 7.3 (2.9, 16.3) | 5.9 (2.0, 18.6) |
| PPES | 76 (29) | 9 (3) | 5.9 (3.1, 12.0) | 20.0 (8.6, 32.1) |
IQR, interquartile range, PPES, palmar-plantar erythrodysesthesia syndrome
a Includes diarrhea, colitis, bowel movement irregularity, frequent bowel movements, functional gastrointestinal disorder, gastrointestinal disorder, and change in bowel habit
b Includes macule, papule, rash, rash erythematous, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic